Goldman Sachs Reinstates Buy on Tarsus Pharmaceuticals, Announces $116 Price Target

Benzinga · 2d ago
Goldman Sachs analyst Andrea Newkirk reinstates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and announces $116 price target.